ibrexafungerp (Brexafemme)
Jump to navigation
Jump to search
Indications
- treatment of vaginal yeast infections (FDA-approved)[2]
Contraindications
Dosage
- one day oral therapy
Tabs: 150 mg
Antimicrobial activity
Adverse effects
Drug interactions
- CYP3A inhibitor
More general terms
References
- ↑ Gamal A, Chu S, McCormick TS et al Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata. Front. Cell. Infect. Microbiol., 11 March 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33791244 PMCID: PMC8006402 Free PMC article https://www.frontiersin.org/articles/10.3389/fcimb.2021.642358/full
- ↑ 2.0 2.1 Frellick M FDA Approves Ibrexafungerp for Vaginal Yeast Infection. Medscape - Jun 02, 2021. https://www.medscape.com/viewarticle/952312